# PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

Source: https://onco.cc/trials/nct07069595/  
OnCo record `nct07069595` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.

## Summary

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease is a phase 2, interventional study registered as NCT07069595 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 78 participants, started 2026-02-26 and due to reach its primary completion in 2031-11-01. Interventions recorded: Datopotamab deruxtecan; Circulating tumor DNA (ctDNA) testing. Conditions listed: Breast Cancer; Residual Disease; Triple Negative Breast Cancer (TNBC); Stage II/III. Triple-negative eligibility wording from the registry: "* Histological confirmation of TNBC defined by ER/PR \<10%, HER2 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PREDICT-RD
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07069595
- Phase: 2
- Setting: PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC With Residual Disease
- Sponsor: UNC Lineberger Comprehensive Cancer Center
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT07069595: https://clinicaltrials.gov/study/NCT07069595

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07069595.json